S.Korea’s CDMO giant Samsung Biologics to offer CRO services
Samsung Biologics Co., the world’s largest contract drugmaker, will enter the contract research organization (CRO) market by leveraging its va...
Celltrion unveils cancer medicine to expand new drug pipelines
South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...
Mediaiplus aims to be the Amazon of clinical trials
Mediaiplus Inc., South Korea’s only provider of data analytics and contract research organization (CRO) matching services for clinical trials,...
LG’s telecom unit looks to lure foreigners with more K-pop-themed shops
LG Uplus Corp., South Korea’s No. 3 mobile carrier, is set to lure foreign customers by opening K-pop-themed stores in the country's major sho...
Celltrion gets FDA nod for Keytruda copy's phase 3 clinical trials
Celltrion Inc., South Korea’s biosimilar giant, will proceed with phase 3 trials for global blockbuster drug Keytruda’s copycat CT-P51, ...
Celltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman
WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...
Samsung gains upper hand vs Netlist in $303 million patent dispute
Samsung Electronics Co. has taken the upper hand in its ongoing legal battle against Netlist Inc. over memory chip module patent infringement allega...
Global quest to find modern elixirs enters new chapter
NEW YORK/ BOSTON – Longevity has long been the dream of humankind. China’s first emperor Qin Shi Huang was obsessed with finding magic e...
Aprogen gets OK Phase 3 trials in India for Herceptin biosimilar
South Korea’s biopharmaceutical company Aprogen Inc. announced on Monday that its Phase 3 clinical trial for a biosimilar of Herceptin (trastu...
JW Pharma takes gout drug Epaminurad to Malaysia for phase 3
South Korea's JW Pharmaceutical Corp., announced on Monday that it has received approval from the Malaysian National Pharmaceutical Regulatory Age...
LG Chem out-licenses obesity drug candidate to US firm
LG Chem Ltd. has agreed to license out a rare genetic obesity drug candidate in phase 2 clinical trials to Rhythm Pharmaceuticals Inc., a US biotech...
MedPacto gets FDA OK for colorectal cancer drug clinical trial
South Korea's biotech company MedPacto Inc. announced on Tuesday that it has got approval from the US Food and Drug Administration (FDA) for its I...
CGBio gets FDA approval for Novosis Putty
South Korea's bio-regenerative medical firm CGBio announced on Tuesday that its Novosis Putty has been designated as a breakthrough device by the US...
SK Bioscience applies Phase 3 trials in US for pneumococcal vaccine
South Korea's SK Bioscience Co. announced on Monday that it submitted the Investigational New Drug (IND) application for the Phase 3 clinical trial ...
Celltrion applies for approval in Europe for eye treatment biosimilar
South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it applied for approval from the European Medicines Agency (EMA) for ...
NKMax to perform first tests on dementia cell therapy in US
NKMax Co., South Korea's largest developer of natural killer (NK) cell therapies, will conduct its first clinical trials in the US for its candidate...
Hanmi Pharma’s Phase 3 trials for anti-obesity medicine approved
South Korea’s Hanmi Pharmaceutical Co. on Monday said the Ministry of Food and Drug Safety approved Phase 3 clinical trials for the company&...
Humedix gets gov't OK for trials of dementia candidate drug
South Korea’s Humedix Co., a developer of biological and pharmaceutical products, on Tuesday said it received approval from the Ministry of Fo...
NKMax's US subsidiary listed on Nasdaq
South Korean natural killer (NK) cell drugmaker NKMax Co. on Wednesday said its US subsidiary NKGen Biotech on Monday was listed on the Nasdaq Globa...
JW Pharma to conduct Phase 3 trials in Thailand for gout treatment
South Korea's JW Pharmaceutical Corp. on Thursday said it received approval from Thailand's Food and Drug Administration to conduct Phase 3 clinical...
Genome & Co.’s bile duct cancer drug candidate enters Phase 2 trials
Genome & Company, a South Korean developer of microbiome-based drugs, on Tuesday said its GEN-001, a leading immunotherapy drug candidate for bi...
Daewoong to develop eye drops for diabetic retinopathy
South Korea's Daewoong Pharmaceutical is venturing into the development of a product that can easily treat diabetic retinopathy in the form of ...
HMM embarks on biofuel ship pilot testing on global route
South Korea has begun a pilot operation of a biofuel-powered container ship on a global route, the government said on Friday. HMM Co.'s container sh...
VaxCell Bio's treatment shows promise for advanced liver cancer
South Korea's VaxCell Biotherapeutics Co. on Tuesday said its treatment for advanced liver cancer under development stopped or greatly reduced the g...
Wellmarker Bio signs worth of $528 mn tech transfer deal
Wellmarker Bio, South Korea's oncology drug development company, announced on Monday that it has signed a technology transfer agreement with a Europ...
AriBio applies for Phase 3 clinical trials in China for oral dementia drug
South Korean clinical-stage biotech company AriBio Co. on Thursday said it applied for Phase 3 clinical trials on the anti-Alzheimer's candidate t...
Yungjin Pharm's new drug candidate gets Fast Track from FDA
South Korea's Yungjin Pharm has secured Fast Track designation from the US Food and Drug Administration (FDA) for its new drug candidate KL1333, des...
Hanmi Pharm to start global clinical trials for immune-oncology drug
South Korea's Hanmi Pharmaceutical Co. announced on Tuesday that it has received approval for the phase 1 clinical trial plan of the immune-oncology...
JW Pharma gets OK for phase 3 clinical trials of URC102 in Taiwan
South Korea's JW Pharmaceutical has won approval from Taiwan's Food and Drug Administration (TFDA) to conduct phase 3 clinical trials for its gout t...
ABL Bio gets OK for phase 1 clinical trials for immune-oncology drug
New drug development company ABL Bio Inc. announced on Thursday that it has received approval from the Ministry of Food and Drug Safety of South Kor...
